Cautious Approach Needed to HTPs' Harm Reduction Claims: Study

Nov.11.2022
Cautious Approach Needed to HTPs' Harm Reduction Claims: Study
A new study warns that current evidence on heated tobacco products (HTPs) doesn't meet standards, and claims of harm reduction should be taken with caution.

The author of a new study published in "Tobacco Control" has stated that the quality of existing evidence regarding heated tobacco products (HTPs) is insufficient and policymakers should be cautious about claims of harm reduction.


In recent years, HTPs have become popular and supporters insist that they pose less harm to health than traditional cigarettes. However, researchers from the University of Bath argue that the evidence supporting these claims largely fails to account for real-world usage and is subject to a high risk of bias.


In their analysis of 40 publicly disclosed HTP clinical trials, 29 of which were affiliated with or sponsored by the tobacco industry, researchers determined that the majority of existing clinical trials have a "high risk of bias" based on their methods and study design.


The most common reason for research to be at high risk of bias is performance bias, which occurs when participants and those conducting the test are aware of the intervention measures being assigned. Additionally, failure to report all result data from the trial measurements is a flaw known as selective reporting bias.


The author believes that the existence of biases has damaged the validity of the experiment, which may lead to an overestimation of the effectiveness of HTP. They also found further limitations in the experiment, including a short duration, restrictive conditions that do not reflect real-world situations, and a lack of relevant comparators, such as e-cigarettes.


The tobacco control research group in Bath says that more detailed independent studies are necessary to evaluate the short and long-term health effects of HTPs.


At the same time, they believe that consumers should be wary of claims of harm reduction, and policymakers and regulators should carefully consider the role of these trials when making decisions surrounding HTPs.


In recent years, there has been significant development in the heated tobacco market in the UK and around the world. According to Sophie Braznell, Chief Researcher at Bath Health Authority, this growth is premised on the notion that these products are healthier than traditional cigarettes.


Our analysis indicates that the situation is far from clear. Clinical trials used by the tobacco industry to support these claims are often inadequate in terms of research methods and reporting, and most are somehow linked to the tobacco industry.


As more and more consumers are turning away from cigarettes and towards these new generation products, there is a need for better evidence to evaluate their current and future health impact. At the same time, the jury is still out on their potential benefits.


The findings related to clinical trials on heated tobacco products are very important, and we need to remain vigilant about the health claims made," added Gemma Taylor, a co-author of the research report from the Addiction and Mental Health Group and Department of Psychology at the University of Bath.


However, at the same time, it is important to note the clear distinction between "heated tobacco products" and "electronic cigarettes". Consumers and health policy makers must not equate the potential benefits of electronic cigarettes in helping people quit smoking with heated tobacco products.


Statement:


This article is compiled from third-party information and is only intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is solely for the purpose of industry exchange and research.


Due to limitations in the translation skills, the translated article may differ from the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all statements and positions related to domestic issues, as well as those involving Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Reuters: The US FDA, under pressure from the White House, will complete its review of nicotine pouches such as ZYN, VELO, and on! by the end of December
Reuters: The US FDA, under pressure from the White House, will complete its review of nicotine pouches such as ZYN, VELO, and on! by the end of December
The U.S. FDA will launch a pilot program to accelerate reviews of nicotine pouch products from Philip Morris International, Altria, BAT’s Reynolds American, and Turning Point Brands, aiming to complete the process by December 2025. The move, driven by pressure from the Trump administration, seeks to address past multi-year approval delays. Nicotine pouches, the fastest-growing U.S. smoking alternative, are seen as lower-risk but raise youth appeal concerns.
Sep.08
19-Year-Old Arrested for Selling Drugs Near Elementary School, Facing Up to 4 Years in Prison
19-Year-Old Arrested for Selling Drugs Near Elementary School, Facing Up to 4 Years in Prison
19-year-old Krisopher Halterman arrested for selling drugs to minors near a Michigan elementary school, facing up to 4 years in prison.
Sep.12 by 2FIRSTS.ai
Plonq Makes Vaping Great Again: How Innovation Helps the Company Strengthen Its Leadership
Plonq Makes Vaping Great Again: How Innovation Helps the Company Strengthen Its Leadership
Moscow, August 30–31, 2025 — Plonq, key partner of VCS, launched the smart POD Meta Smart and STELS chewing tobacco, reinforcing its 30%+ market share and leadership in Russia’s new nicotine sector.
Sep.16
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most
In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.
Oct.21
Product | Following the discontinuation of the AF5000, ELFBAR launches compliant alternative AF5500 in the UK.
Product | Following the discontinuation of the AF5000, ELFBAR launches compliant alternative AF5500 in the UK.
ELFBAR has launched the AF5500 in the UK, featuring a 12ml e-liquid capacity. Both its appearance and naming are similar to the popular "2+10" product, the AF5000, which was previously a bestseller in the region. The AF5000 has been removed from the market due to the disposable vape ban, and the AF5500 is likely to be its compliant alternative.
Sep.05 by 2FIRSTS.ai
Company | CCELL Launches New GemBar Device with Transparent Tank and Postless Design
Company | CCELL Launches New GemBar Device with Transparent Tank and Postless Design
CCELL has unveiled GemBar via its LinkedIn channel—a new vaporization device featuring a transparent tank for instant capacity checks and a postless design aimed at boosting efficiency and preserving flavor. The company underscores a reliability-first experience, pledging: “We respect every puff. No clogs. No leaks. No burnt taste.”
Sep.15 by 2FIRSTS.ai